NCT06887192招募中2 期
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 56
- 主要终点
- Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score
研究概览
简要总结
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).
The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent, or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:
- •The participant's LAR must provide written informed consent AND
- •The participant will provide informed assent.
- •Meets clinical criteria for Possible AD or Probable AD.
- •Presence of psychotic symptoms (meeting International Psychogeriatric Association criteria) (Cummings 2020) for at least 2 months before Screening.
- •Has resided at the same home, residential assisted living, or nursing home facility for a minimum of 6 weeks before Screening.
- •Has a designated care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug.
- •Has a NPI-C H+D score of ≥ 6 AND meet at least 1 of the following criteria:
- •Moderate to severe delusions, defined as NPI-C Delusions domain score of ≥ 2 on at least 2 of the 8 items OR
- •Moderate to severe hallucinations, defined as NPI-C Hallucinations domain score of ≥ 2 on at least 2 of the 7 items.
- •Has a (CGI)-S hallucinations and delusions domain-specific score ≥4
- •Has an Mini-mental State Examination (MMSE) score of 6 to 26, inclusive.
排除标准
- •Under the care of hospice, bed-bound, or receiving end-of-life palliative care.
- •Psychotic symptoms that are primarily attributable to substance abuse or a medical, neurological or psychiatric condition other than Alzheimer's disease.
- •Evidence of a CNS disorder other than Alzheimer's disease that is the primary cause of, or a significant contributor to the participant's dementia.
- •Moderate or severe major depressive episode within 3 months of Screening, according to DSM-5 criteria.
- •Has an elevated risk of suicidal behavior
- •Has had an amyloid PET brain scan or CSF Alzheimer's disease biomarker test in the past 3 years with results inconsistent with a diagnosis of AD.
- •Evidence of a clinically significant and/or unstable medical condition that, in the opinion of the investigator or medical monitor, could substantially impair cognition, compromise participant safety, interfere with the participant's ability to comply with study procedures or substantially impair the evaluation of efficacy or safety assessments.
- •Gastric retention, urinary retention or narrow-angle (angle-closure) glaucoma
- •Meets or has met DSM-5 criteria for alcohol or substance use disorder within the past 12 months (excluding caffeine and nicotine).
- •Has previously participated in any clinical study with ML-007 or ML-007C-MA.
- •Has developed an allergy or other intolerance to ML-007C-MA, its active ingredients or their excipients.
- •Received or may have received an investigational drug, biological product or device within 90 days before Baseline (or 6 months for investigational Alzheimer's disease-modifying therapies).
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
ML-007C-MA
Experimental
干预措施: ML-007C-MA (Drug)
结局指标
主要结局
Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score
时间窗: Baseline and End of Treatment (7 weeks)
NPI-C H+D scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.
次要结局
- Change from Baseline to End of Treatment in the Clinical Global Impressions-Severity (CGI-S) hallucinations and delusions domain-specific score(Baseline and End of Treatment (7 weeks))
- Change from Baseline to End of Treatment in the Neuropsychiatric Inventory - Clinician Agitation and Aggression (NPI-C A+A) score in participants who have a CGI-S agitation/aggression domain-specific score of ≥4 at Baseline(Baseline and End of Treatment (7 weeks))
研究者
研究点 (56)
Loading locations...
相似试验
已完成
1 期
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)Influenza InfectionNCT05818124Merck Sharp & Dohme LLC161
撤回
2 期
Study of MB07811 in Subjects With HypercholesterolemiaHypercholesterolemiaNCT00879112Ligand Pharmaceuticals80
已完成
2 期
The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection FractionCardiac FailureNCT02932566Manchester University NHS Foundation Trust129
已完成
2 期
Arbaclofen in Children and Adolescents With ASDAutism Spectrum DisorderNCT03682978Celso Arango, MD, PhD124
已完成
2 期
Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.Prostatic NeoplasmNCT03361969Pantarhei Oncology B.V.63